TD Cowen upgrades Humana to buy and raises price target to $485
TD Cowen upgraded Humana Inc. (HUM) from hold to buy and raised its price target from $430 to $485. The new target stood 27.6% above Humana's November 19 closing price of $380. TD Cowen's review of a sample of Humana's 2027 Medicare Advantage plans found lower allowances for over-the-counter products, higher out-of-pocket limits and changes in the cost of some drugs.
In 30 seconds
- TD Cowen moved its rating on Humana from hold to buy.
- The price target rose from $430 to $485, 27.6% above the November 19 close of $380.
- The review of a sample of 2027 Medicare Advantage plans found lower allowances for over-the-counter products.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.